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Retention of 2-deoxy-2-[18F]fluoro-D-glucose 18F-FDG in the bladder causes more prob-
lems in small animal research than in human research owing to the smaller size of the sub-
ject. Catheterization has been proposed to reduce bladder spillover both in human studies
and in small animal research. Noninvasive alternatives such as hydration plus furosemide
also seem to be a promising pre-imaging strategy for decreasing bladder spillover. Our main
goal was to measure the effects of the combination of furosemide and hydration for reducing
bladder signal directly on mouse bowel 18F-FDG-PET images.
Methods
Nine mice were divided into two groups: the control group (C, n = 4) and the treatment group
(n = 5). The clearance protocol combines hyperhydration and a single furosemide dose dur-
ing the 18F-FDG uptake period. Two images were acquired on different days in treated mice
to evaluate two different furosemide doses (low dose, LD, 3.5 mg/kg; and high dose, HD, 7
mg/kg). A region of interest was drawn on each computed tomography image (bladder, kid-
neys, liver, muscle, and bone marrow). To quantify bladder spillover, two different areas of
the colon were selected.
Results
A remarkable reduction in bladder spillover was achieved on 18F-FDG -PET in both groups.
Our imaging findings were quantified, and both furosemide doses induced a decrease in
mean standard uptake values (SUVmean) compared with the controls (LD 1.46 ± 0.54 and
HD 1.05 ± 0.29; controls: 8.90 ± 3.4 [p-value < 0.05]).
Conclusion
We validated a non-invasive, easy, and harmless pre-imaging alternative for decreasing
18F-FDG bladder spillover. Our study shows the effect of furosemide on bladder spillover
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cle, and bone marrow.
Introduction
Clinical and preclinical applications of 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG) positron
emission tomography (PET) are increasingly used in a wide variety of disciplines such as
oncology [1], cardiology [2, 3], neuroscience [4], and inflammatory and infectious diseases [5,
6]. Although unspecific uptake of 18F-FDG results in the well-known problem of detectability
in several applications [7, 8], accumulation of urine also constitutes a relevant limitation of
this radiotracer [9]. The accumulation mechanism depends on the fluorine atom in the mole-
cule, which reduces the affinity of 18F-FDG for sodium-glucose linked transporter 1 on the
proximal tubules of the nephron, thus decreasing reabsorption [10, 11] and, consequently,
increasing elimination of 18F-FDG from urine. The accumulation of activity in the bladder
leads to spillover, which may hamper visualization of neighboring lesions such as gynecologi-
cal cancers [12], bladder wall malignances [13], and inflammatory bowel diseases (IBD) [5].
Spillover is more important in small animal research than in human studies owing to the
smaller size of the subjects, their faster metabolism, and their higher excretion rates, which
lead to rapid bladder refilling [14]. Several methods have been proposed [15] to reduce the
18F-FDG signal in the bladder. Non-invasive alternatives are based on the use of saline hydra-
tion with or without concurrent administration of diuretic [11, 16]. These methods focus
mainly on the evaluation of 18F-FDG in urine, but do not explore its actual effects on the PET
image, which remain largely unknown. Accordingly, our main goal was to measure the effects
of the combination of furosemide and hydration for reducing bladder signal directly on mouse
bowel 18F-FDG-PET images.
Materials and methods
All mice were housed in cages under the same conditions (ad libitum access to food and water,
with 12 h of light and 12 h of darkness).
Nine mice were divided into two groups, the control group (C, n = 4) and treatment group
(n = 5). Animals fasted overnight before PET-CT acquisition (ARGUS scanner, SEDECAL,
Madrid). Scans were performed under inhaled anesthesia (isoflurane: 5% for induction and
2% for maintenance). Control animals (under no treatment) underwent a single PET-CT
study. Two PET-CT images were acquired on different days from the treated mice to evaluate
the bladder clearance protocol.
Bladder clearance protocol
Fig 1 shows the steps followed to prevent accumulation of 18F-FDG in the bladder. Treated
animals were hydrated by administering two subcutaneous (SC) saline boluses 45 and 25 min-
utes before image acquisition (time point zero in Fig 1). A single intraperitoneal (IP) dose of
furosemide was administered together with the last saline bolus. Two furosemide doses were
tested on different days: low dose, LD, 3.5 mg/kg; and high dose, HD, 7 mg/kg; simultaneously
with the second saline bolus, 25 minutes before PET acquisition. In both control and treated
animals, urination was forced by manual bladder compression to minimize the bladder signal
before the animal was placed inside the PET scanner.
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Image acquisition
A 30-minute PET image (prone position) was first acquired followed by a CT image using an
X-ray beam current of 240 μA and a tube voltage of 40 kVp. Forty-five minutes before the PET
scan, every mouse received an intravenous injection of 19.4 ± 1.8 MBq 18F-FDG. Before imag-
ing, the animals also received 0.3 ml iopamidol intraperitoneally (Iopamiro, Bracco Imaging S.
p.A, Italy) to delimit the external border of organs and 0.5 ml of gastrolux contrast agent in the
rectum [17] (Iberoinvesa Pharma S.L, Spain) to enhance the internal lumen of the colon. PET
images were reconstructed using OSEM-2D, with 50 subsets and 2 iterations. CT images were
reconstructed using an FDK algorithm [18].
Image analysis
For each image, regions of interest (ROIs) were drawn on the CT image. These included the
bladder, kidneys, liver (0.04±0.01 cc of the left lateral lobe), muscle, small intestine and bone
marrow (left ilium). Bladder spillover was quantified as the ratio between SUVmean of distal
colon and SUVmean of middle colon. These two different colon areas were selected as follows:
a portion of the middle colon as a region at some distance from the bladder and a portion of
the distal colon as a region near the bladder. ROIs were transferred to the PET study to mea-
sure their mean standard uptake values (SUVmean). Total bladder radioactivity was also mea-
suring to support SUVmean results and evaluate possible bladder volume effects. Additionally,
bladder volume (cc) was measured on the CT.
Statistical analysis
Results are presented as mean ± SD. The Kruskal-Wallis test was used to statistically assess differ-
ences in SUVmean between the groups. The Wilcoxon test was used for paired comparisons (LD
vs. HD) and Levene test for the variability. Statistical significance threshold was set at p< 0.05.
Animal ethics statement
Mice were housed in the animal facility of Hospital General Universitario Gregorio Marañón,
Madrid, Spain (ES280790000087). All animal procedures conformed to EU Directive 2010/
Fig 1. Bladder clearance protocol. Zero time corresponded to the PET acquisition. Forty-five minutes before the scan, the animals received 19.4 MBq of 18F-FDG. CT
contrasts (iopamiro and gastrolux) were administered immediately before acquisition. Treated animals received two SC saline injections (-45 min and -25 min) and a
dose of furosemide (-25 min). �Administration only in treated animals; LD = low dose, 3.5 mg/kg; HD = high dose, 7 mg/kg; SC = subcutaneous; IP = intraperitoneal;
and IV = intravenous.
https://doi.org/10.1371/journal.pone.0205610.g001
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63EU and national regulations (RD 53/2013) and were approved by the local ethics commit-
tees and the Animal Protection Board of the Comunidad Autónoma de Madrid (PROEX 204/
14).
Results
Fig 2A shows examples of PET-CT images from each group. 18F-FDG-PET activity in the blad-
der was markedly reduced in both treated groups compared with the control mice. Our visual
findings were quantified, and both furosemide doses induced a decrease in bladder SUVmean
compared with the controls (LD 1.46 ± 0.54 and HD, 1.05 ± 0.27; controls, 8.90 ± 3.4 [p <
0.05]). Total bladder radioactivity counts also decreased with both furosemide doses (LD 1.49
x 105 ± 4.92 x 104 and HD, 7.40 x 104 ± 3.19 x 104) compared with controls (2.89 x 105 ± 4.28 x
104, [p< 0.05]). In addition, a larger variability was observed in the control group (3.4 vs. 0.54
in LD and 0.29 in HD; [p = 0.012]), coefficient of variation is higher in controls (38.2%) com-
pared with HD (26.0%). The bladder clearance protocol also enabled a clear increase in blad-
der volume in treated animals compared with the control group, although the difference was
not statistically significant (Fig 2C).
No differences were observed for 18F-FDG uptake in bone marrow and muscle (Fig 2D).
Liver uptake increased in both treated groups (LD, 0.56 ± 0.10; HD, 0.55 ± 0.09) compared
with controls (0.39 ± 0.03; p-value < 0.05). A slight increase was also observed in the kidneys
and small intestine, although, again, the differences were not statistically significant.
Colon uptake ratio (SUVmean of distal colon / SUVmean of middle colon, as explained
above) was used to assess the effect of bladder spillover. Fig 3A shows the location of these
colon regions in the sagittal plane. Colon uptake ratios were clearly reduced in the treated
groups (LD, 1.09 ± 0.06; HD, 1.21 ± 0.06) compared with the control animals (1.9 ± 0.97), thus
quantitatively confirming the decrease in bladder spillover when the clearance protocol is
applied (Fig 3B). The high dose (7 mg/kg) induced a slight decrease in 18F-FDG uptake in the
bladder compared with LD (p = 0.043), liver (p = 0.70), kidneys (p = 0.5), and small intestine
(p = 0.35). Moreover, bladder volume was smaller than with the low dose (p = 0.5), although
the differences were not statistically significant.
Discussion
In this work we assess a non-invasive, easy, and harmless pre-imaging procedure to decrease
accumulation of 18F-FDG in the bladder. This clearance protocol combines hyperhydration
with a single furosemide dose during the 18F-FDG uptake period. Our study quantifies the
effect on 18F-FDG-PET images by measuring the SUVmean of the bladder bone marrow, liver,
muscle, small intestine and colon in order to assess bladder spillover.
Previous studies [11, 16] evaluated the effect of administering a diuretic by directly quanti-
fying 18F-FDG in excreted rodent urine under various experimental conditions, such as long
pre-hydration periods (IP saline administration 2.5 hours before 18F-FDG injection [16] and
IV saline infusion before and during the 18F-FDG-PET experiment [11]). To our knowledge,
our study is the first to quantify the effect of the proposed protocol on 18F-FDG-PET images.
Our results for bladder uptake also show a decreased standard deviation in treated animals,
indicating that the pre-imaging procedure helps to homogenize the studies, as the amount of
spillover would be more constant across subjects.
Previous studies in both clinical research [15, 19, 20] and preclinical research [16] con-
cluded that the key to obtaining satisfactory bladder clearance is the optimal time of furose-
mide injection with respect to 18F-FDG administration [15, 16, 19, 20], although this timing
has not yet been established in rodent 18F-FDG-PET imaging. We had observed that the
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Fig 2. PET-CT images. (A) Coronal PET (red scale, cps x 10−3) and CT (gray scale) images of a control animal (C), low dose (LD, 3.5 mg/kg), and high dose (HD, 7 mg/
kg). The bladder signal (arrow) is lower in treated animals than in controls. (B) Both furosemide doses led to a reduction in bladder SUVmean compared with the
control group. (C) Bladder volume of the treated animals is slightly higher than the controls. (D) Non-significant differences were observed in kidney, bone marrow,
small intestine and muscle uptake, although an increase in SUVmean was observed in the liver. �p< 0.05.
https://doi.org/10.1371/journal.pone.0205610.g002
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bladder clearance protocol (saline with furosemide) takes effect 15–20 minutes after adminis-
tration (S1 Fig). Additionally, in rodents, excretion of 18F-FDG occurs during the first 30 min-
utes after administration, with decreased blood levels [11]. Taking both observations together
(optimal time for furosemide and 18F-FDG excretion) we chose to administer furosemide 25
minutes after the 18F-FDG injection, assuming that the diuretic effect of furosemide begins
close to the moment when the 18F-FDG blood concentration decreases. Our hypothesis was
confirmed after analyzing the 18F-FDG-PET images, because the timing selected reduced the
bladder signal (Fig 2A), with no marked effects on surrounding tissues such as muscle, small
intestine and bone marrow (Fig 2D).A secondary effect of furosemide is the increased bladder
volume, well described in patients and that may be helpful for the visualization of bladder wall
malignances [15]. However, in our study we observed that bladder volume increase may com-
press and displace adjacent organs, such as the colon, thus hampering visualization. Despite
this possible negative effect, we are already routinely using the high furosemide dose combined
with hyperhydration in mouse models with abdominal PET imaging, such as Crohn’s disease,
infectious colitis and prostate cancer.
The excellent bladder suppression we achieved is consistent with the observations of
Kosuda et al. [16], who reported an increase in 18F-FDG uptake in several tissues (liver, kidney,
small intestine, heart, etc.), which agree with our findings (Fig 2D). Kidney and liver are the
organs that are most susceptible to furosemide [21]. Foy et al. [22] showed a significant reduc-
tion in liver glycogen 1 hour after IP administration of the 200 mg/kg dose of furosemide, pos-
sibly indicating an increase in liver metabolism and, therefore, an increase in 18F-FDG uptake.
We did not observe any difference between the groups for uptake of 18F-FDG in bone marrow,
small intestine and muscle.
Fig 3. Evaluation of bladder spillover. (A) Sagittal PET (red scale) and CT (grey scale) image of mouse abdomen showing selected areas of the colon. (B) Ratio between
the distal colon and middle colon (n = 3 per group). HD, high furosemide dose (7 mg/kg); LD, low furosemide dose (3.5 mg/kg).
https://doi.org/10.1371/journal.pone.0205610.g003
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To evaluate the effects of bladder clearance, we measured uptake of 18F-FDG in the distal
and middle colon (Fig 3). Both areas have equivalent 18F-FDG uptake (ratio close to one),
whereas the control animals showed almost double the uptake ratio in the distal colon. There-
fore, the protocol we propose clearly reduces bladder spillover in the colon.
Interpretation of the data in this study is limited by the fact that mice are the rodent species
that is most sensitive to furosemide-induced toxicity [21]. Our protocol increases bladder vol-
ume, which may compress and displace adjacent organs, such as the colon, thus hampering
visualization. We observed this problem in four treated animals, forcing us to reduce the sam-
ple size per group for the spillover analyses. This undesirable effect may be reduced by forcing
urination before placing the animal inside the PET-CT device although in our case was not
effective in all the animals. Diuretic drugs reduce blood pressure, and this must be taken into
account if the animals are under treatment with additional drugs. Finally, it must be noted that
the decrease in bladder activity may contribute to an overall better contrast recovery by
increasing other organs uptake, although this effect depends on the system noise-equivalent
counting rate (NEC) and is expected to be small for most commercial PET scanners at the
dose levels used here.
In conclusion, we characterized a non-invasive and effective pre-imaging protocol that
reduces accumulation of 18F-FDG in urine. Our pre-imaging protocol is based on the combi-
nation of hyperhydration and furosemide during the 18F-FDG uptake period. With the excep-
tion of the liver, our pre-imaging protocol did not reveal alterations in tissue uptake measured
directly on the PET images. Furthermore, we demonstrated that it is an effective method for
decreasing bladder spillover in neighboring organs such as the colon.
Supporting information
S1 Fig. Urination effects of hydration and furosemide. (a) Minute 0 was chosen as reference
coinciding with the furosemide administration in treated groups. Every animal received two
subcutaneous (SC) saline boluses at minutes -20, and 0. �Treated groups (LD and HD) addi-
tionally received an intraperitoneal (IP) bolus of furosemide (0-time, total volume of 0.2 ml).
(b) Time course of voiding. Points represent means of three mice per group. LD: low dose of
furosemide group (3.5 mg/kg) and HD: High dose of furosemide group (7 mg/kg).
(TIF)
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References
1. Almuhaideb A, Papathanasiou N, Bomanji J. (18)F-FDG PET/CT Imaging In Oncology. Annals of Saudi
Medicine. 2011; 31(1):3–13. https://doi.org/10.4103/0256-4947.75771 PubMed PMID: PMC3101722.
PMID: 21245592
2. Yu JQ, Doss M, Codreanu I, Zhuang H. PET/CT in Patients with Sarcoidosis or IgG4 Disease. PET Clin-
ics. 2012; 7(2):191–210. https://doi.org/10.1016/j.cpet.2012.01.005 PMID: 27157236
3. Gargiulo S, Greco A, Gramanzini M, Petretta MP, Ferro A, Larobina M, et al. PET/CT Imaging in Mouse
Models of Myocardial Ischemia. Journal of Biomedicine and Biotechnology. 2012; 2012:12. https://doi.
org/10.1155/2012/541872 PMID: 22505813
4. Bohnen NI, Djang DSW, Herholz K, Anzai Y, Minoshima S. Effectiveness and Safety of 18F-FDG PET
in the Evaluation of Dementia: A Review of the Recent Literature. Journal of Nuclear Medicine. 2012; 53
(1):59–71. https://doi.org/10.2967/jnumed.111.096578 PMID: 22173840
5. Glaudemans AWJM, de Vries EFJ, Galli F, Dierckx RAJO, Slart RHJA, Signore A. The Use of (18)F-
FDG-PET/CT for Diagnosis and Treatment Monitoring of Inflammatory and Infectious Diseases. Clinical
and Developmental Immunology. 2013; 2013:623036. https://doi.org/10.1155/2013/623036 PubMed
PMID: PMC3763592. PMID: 24027590
6. Bettenworth D, Reuter S, Hermann S, Weckesser M, Kerstiens L, Stratis A, et al. Translational 18F-
FDG PET/CT Imaging to Monitor Lesion Activity in Intestinal Inflammation. Journal of Nuclear Medicine.
2013; 54(5):748–55. https://doi.org/10.2967/jnumed.112.112623 PMID: 23516311
7. Lum DP, Wandell S, Ko J, Coel MN. Reduction of myocardial 2-deoxy-2-[18F]fluoro-D-glucose uptake
artifacts in positron emission tomography using dietary carbohydrate restriction. Mol Imaging Biol.
2002; 4(3):232–7. Epub 2003/10/11. doi: S1095039701000620 [pii]. PMID: 14537127.
8. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and
benign variants. Radiographics. 1999; 19(1):61–77; quiz 150–1. Epub 1999/01/30. https://doi.org/10.
1148/radiographics.19.1.g99ja0761 PMID: 9925392.
9. Agarwal KK, Roy SG, Kumar R. Diuretic 18F-Fluorodeoxyglucose PET/Computed Tomography in Eval-
uation of Genitourinary Malignancies. PET Clin. 2016; 11(1):39–46. Epub 2015/11/23. https://doi.org/
10.1016/j.cpet.2015.07.005 S1556-8598(15)00080-2 [pii]. PMID: 26590442.
10. Kleinzeller A, McAvoy EM, McKibbin RD. Active renal hexose transport. Structural requirements. Bio-
chim Biophys Acta. 1980; 600(2):513–29. Epub 1980/08/04. PMID: 7407126.
11. Moran JK, Lee HB, Blaufox MD. Optimization of urinary FDG excretion during PET imaging. J Nucl
Med. 1999; 40(8):1352–7. Epub 1999/08/18. PMID: 10450688.
12. Pandit-Taskar N. Oncologic Imaging in Gynecologic Malignancies. Journal of Nuclear Medicine. 2005;
46(11):1842–50. PMID: 16269598
13. Kumar R, Zhuang H, Alavi A. PET in the management of urologic malignancies. Radiologic Clinics.
2004; 42(6):1141–53. https://doi.org/10.1016/j.rcl.2004.08.007 PMID: 15488563
14. Deleye S, Heylen M, Deiteren A, De Man J, Stroobants S, De Winter B, et al. Continuous flushing of the
bladder in rodents reduces artifacts and improves quantification in molecular imaging. Mol Imaging.
2014;13. Epub 2014/05/16. https://doi.org/10.2310/7290.2014.00013 PMID: 24825484.
15. Nijjar S, Patterson J, Ducharme J, Leslie WD, Demeter SJ. The effect of furosemide dose timing on
bladder activity in oncology imaging with 18F-fluorodeoxyglucose PET/CT. Nuclear Medicine Commu-
nications. 2010; 31(2):167–72. https://doi.org/10.1097/MNM.0b013e32833492eb PubMed PMID:
00006231-201002000-00013. PMID: 19997041
16. Kosuda S, Fisher S, Wahl RL. Animal studies on the reduction and/or dilution of 2-deoxy-2-[18F]fluoro-
D-glucose (FDG) activity in the urinary system. Ann Nucl Med. 1997; 11(3):213–8. Epub 1997/08/01.
PMID: 9310170.
17. Hindryckx P, Staelens S, Devisscher L, Deleye S, De Vos F, Delrue L, et al. Longitudinal quantification
of inflammation in the murine dextran sodium sulfate-induced colitis model using muPET/CT. Inflamm
Bowel Dis. 2011; 17(10):2058–64. Epub 2011/09/13. https://doi.org/10.1002/ibd.21578 PMID:
21910167.
18. Abella M, Vaquero JJ, Sisniega A, Pascau J, Udı́as A, Garcı́a V, et al. Software architecture for multi-
bed FDK-based reconstruction in X-ray CT scanners. Computer Methods and Programs in Biomedi-
cine. 2012; 107(2):218–32. https://doi.org/10.1016/j.cmpb.2011.06.008 PMID: 21908068
Cleaning 18F-FDG bladder signal
PLOS ONE | https://doi.org/10.1371/journal.pone.0205610 October 17, 2018 8 / 9
19. Harkirat S, Anand S, Jacob M. Forced diuresis and dual-phase 18F-fluorodeoxyglucose-PET/CT scan
for restaging of urinary bladder cancers. Indian Journal of Radiology and Imaging. 2010; 20(1):13–9.
https://doi.org/10.4103/0971-3026.59746 PMID: 20351986
20. Anjos DA, Etchebehere EC, Ramos CD, Santos AO, Albertotti C, Camargo EE. 18F-FDG PET/CT
delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med. 2007; 48(5):764–70.
Epub 2007/05/04. doi: 48/5/764 [pii] https://doi.org/10.2967/jnumed.106.036350 PMID: 17475965.
21. McMurtry RJ, Mitchell JR. Renal and hepatic necrosis after metabolic activation of 2-substituted furans
and thiophenes, including furosemide and cephaloridine. Toxicology and Applied Pharmacology. 1977;
42(2):285–300. http://dx.doi.org/10.1016/0041-008X(77)90005-9. PMID: 595008
22. Foy JM, Furman BL. Effect of diuretics on mouse blood sugar following single dose administration. Brit-
ish Journal of Pharmacology. 1971; 42(2):287–97. PubMed PMID: PMC1667152. PMID: 5091161
Cleaning 18F-FDG bladder signal
PLOS ONE | https://doi.org/10.1371/journal.pone.0205610 October 17, 2018 9 / 9
